{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:53:46Z","timestamp":1790495626192,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["5480"],"award-info":[{"award-number":["5480"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["7972"],"award-info":[{"award-number":["7972"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["R.G.P 2\/90\/41"],"award-info":[{"award-number":["R.G.P 2\/90\/41"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Protein J"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10930-020-09945-6","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T20:14:20Z","timestamp":1610741660000},"page":"296-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4819-2040","authenticated-orcid":false,"given":"Mahmoud A. A.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3527-0126","authenticated-orcid":false,"given":"Alaa H. M.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-9835","authenticated-orcid":false,"given":"Khaled S.","family":"Allemailem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-6402","authenticated-orcid":false,"given":"Ahmad","family":"Almatroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-9875","authenticated-orcid":false,"given":"Mahmoud F.","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0343-4969","authenticated-orcid":false,"given":"Mohamed-Elamir F.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"9945_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270\u2013273. https:\/\/doi.org\/10.1038\/s41586-020-2012-7","journal-title":"Nature"},{"key":"9945_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579:265\u2013269. https:\/\/doi.org\/10.1038\/s41586-020-2008-3","journal-title":"Nature"},{"key":"9945_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya AE et al (2020) The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536\u2013544. https:\/\/doi.org\/10.1038\/s41564-020-0695-z","journal-title":"Nat Microbiol"},{"key":"9945_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","volume":"24","author":"MA Shereen","year":"2020","unstructured":"Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R (2020) COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 24:91\u201398. https:\/\/doi.org\/10.1016\/j.jare.2020.03.005","journal-title":"J Adv Res"},{"key":"9945_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1751298","author":"SA Khan","year":"2020","unstructured":"Khan SA, Zia K, Ashraf S, Uddin R, Ul-Haq Z (2020) Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1751298","journal-title":"J Biomol Struct Dyn"},{"key":"9945_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1779133","author":"E Tazikeh-Lemeski","year":"2020","unstructured":"Tazikeh-Lemeski E, Moradi S, Raoufi R, Shahlaei M, Janlou MAM, Zolghadri S (2020) Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1779133","journal-title":"J Biomol Struct Dyn"},{"key":"9945_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/07391102.2020.1791958","volume":"1","author":"MAA Ibrahim","year":"2020","unstructured":"Ibrahim MAA, Abdelrahman AHM, Hegazy MF (2020) In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn 1:12. https:\/\/doi.org\/10.1080\/07391102.2020.1791958","journal-title":"J Biomol Struct Dyn"},{"key":"9945_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","volume":"38","author":"C Harrison","year":"2020","unstructured":"Harrison C (2020) Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 38:379\u2013381. https:\/\/doi.org\/10.1038\/d41587-020-00003-1","journal-title":"Nat Biotechnol"},{"key":"9945_CR9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","volume":"367","author":"K Kupferschmidt","year":"2020","unstructured":"Kupferschmidt K, Cohen J (2020) Race to find COVID-19 treatments accelerates. Science 367:1412\u20131413. https:\/\/doi.org\/10.1126\/science.367.6485.1412","journal-title":"Science"},{"key":"9945_CR10","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.26633\/RPSP.2020.40","volume":"44","author":"SGV Rosa","year":"2020","unstructured":"Rosa SGV, Santos WC (2020) Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publ 44:e40. https:\/\/doi.org\/10.26633\/RPSP.2020.40","journal-title":"Rev Panam Salud Publ"},{"key":"9945_CR11","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"W Yin","year":"2020","unstructured":"Yin W et al (2020) Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368:1499\u20131504. https:\/\/doi.org\/10.1126\/science.abc1560","journal-title":"Science"},{"key":"9945_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel JH et al (2020) Remdesivir for the treatment of covid-19 - preliminary report. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"9945_CR13","unstructured":"Administration FD (2020) Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment. vol. 1."},{"key":"9945_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1790037","author":"MAA Ibrahim","year":"2020","unstructured":"Ibrahim MAA, Abdeljawaad KAA, Abdelrahman AHM, Hegazy MF (2020) Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1790037","journal-title":"J Biomol Struct Dyn"},{"key":"9945_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1784291","author":"M Kandeel","year":"2020","unstructured":"Kandeel M, Abdelrahman AHM, Oh-Hashi K, Ibrahim A, Venugopala KN, Morsy MA, Ibrahim MAA (2020) Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1784291","journal-title":"J Biomol Struct Dyn"},{"key":"9945_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jmv.25726","volume":"92","author":"Z Liu","year":"2020","unstructured":"Liu Z et al (2020) Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 92:595\u2013601. https:\/\/doi.org\/10.1002\/jmv.25726","journal-title":"J Med Virol"},{"key":"9945_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/jmv.25752","volume":"92","author":"N Cimolai","year":"2020","unstructured":"Cimolai N (2020) Potentially repurposing adamantanes for COVID-19. J Med Virol 92:531\u2013532. https:\/\/doi.org\/10.1002\/jmv.25752","journal-title":"J Med Virol"},{"key":"9945_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z et al (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293. https:\/\/doi.org\/10.1038\/s41586-020-2223-y","journal-title":"Nature"},{"key":"9945_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2577-1","author":"L Riva","year":"2020","unstructured":"Riva L et al (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. https:\/\/doi.org\/10.1038\/s41586-020-2577-1","journal-title":"Nature"},{"key":"9945_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202000115","author":"CN Cavasotto","year":"2020","unstructured":"Cavasotto CN, Di Filippo JI (2020) In silico drug repurposing for COVID-19: targeting SARS-CoV-2 proteins through docking and consensus ranking. Mol Inform. https:\/\/doi.org\/10.1002\/minf.202000115","journal-title":"Mol Inform"},{"key":"9945_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202000113","author":"VM Alves","year":"2020","unstructured":"Alves VM et al (2020) QSAR modeling of SARS-CoV Mpro inhibitors identifies sufugolix, cenicriviroc, proglumetacin, and other drugs as candidates for repurposing against SARS-CoV-2. Mol Inform. https:\/\/doi.org\/10.1002\/minf.202000113","journal-title":"Mol Inform"},{"key":"9945_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202000090","author":"V Battisti","year":"2020","unstructured":"Battisti V, Wieder O, Garon A, Seidel T, Urban E, Langer T (2020) A computational approach to identify potential novel inhibitors against the coronavirus SARS-CoV-2. Mol Inform. https:\/\/doi.org\/10.1002\/minf.202000090","journal-title":"Mol Inform"},{"key":"9945_CR23","doi-asserted-by":"publisher","first-page":"104046","DOI":"10.1016\/j.compbiomed.2020.104046","volume":"126","author":"MAA Ibrahim","year":"2020","unstructured":"Ibrahim MAA et al (2020) In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Comput Biol Med 126:104046\u2013104058. https:\/\/doi.org\/10.1016\/j.compbiomed.2020.104046","journal-title":"Comput Biol Med"},{"key":"9945_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1752802","author":"N Muralidharan","year":"2020","unstructured":"Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM (2020) Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1752802","journal-title":"J Biomol Struct Dyn"},{"key":"9945_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1786459","author":"I Ancy","year":"2020","unstructured":"Ancy I, Sivanandam M, Kumaradhas P (2020) Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1786459","journal-title":"J Biomol Struct Dyn"},{"key":"9945_CR26","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart DS et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668\u2013672. https:\/\/doi.org\/10.1093\/nar\/gkj067","journal-title":"Nucleic Acids Res"},{"key":"9945_CR27","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074\u2013D1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Res"},{"key":"9945_CR28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1021\/ci100031x","volume":"50","author":"PC Hawkins","year":"2010","unstructured":"Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT (2010) Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and cambridge structural database. J Chem Inf Model 50:572\u2013584. https:\/\/doi.org\/10.1021\/ci100031x","journal-title":"J Chem Inf Model"},{"key":"9945_CR29","unstructured":"OMEGA (2013), 2.5.1.4 edn. OpenEye Scientific Software, Santa Fe, NM, USA"},{"key":"9945_CR30","unstructured":"SZYBKI OpenEye Scientific Software: Santa Fe, NM, USA."},{"key":"9945_CR31","doi-asserted-by":"publisher","first-page":"W368","DOI":"10.1093\/nar\/gki464","volume":"33","author":"JC Gordon","year":"2005","unstructured":"Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A (2005) H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res 33:W368\u2013W371. https:\/\/doi.org\/10.1093\/nar\/gki464","journal-title":"Nucleic Acids Res"},{"key":"9945_CR32","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ (2016) Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11:905\u2013919. https:\/\/doi.org\/10.1038\/nprot.2016.051","journal-title":"Nat Protoc"},{"key":"9945_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"key":"9945_CR34","volume-title":"AMBER 2016","author":"DA Case","year":"2016","unstructured":"Case DA et al (2016) AMBER 2016. University of California, San Francisco"},{"key":"9945_CR35","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C (2015) ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 11:3696\u20133713. https:\/\/doi.org\/10.1021\/acs.jctc.5b00255","journal-title":"J Chem Theory Comput"},{"key":"9945_CR36","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157\u20131174. https:\/\/doi.org\/10.1002\/jcc.20035","journal-title":"J Comput Chem"},{"key":"9945_CR37","doi-asserted-by":"publisher","first-page":"10269","DOI":"10.1021\/j100142a004","volume":"97","author":"CI Bayly","year":"1993","unstructured":"Bayly CI, Cieplak P, Cornell W, Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J Phys Chem 97:10269\u201310280. https:\/\/doi.org\/10.1021\/j100142a004","journal-title":"J Phys Chem"},{"key":"9945_CR38","volume-title":"Gaussian 09, Revision","author":"MJ Frisch","year":"2009","unstructured":"Frisch MJ et al (2009) Gaussian 09, Revision, E01 edn. Gaussian Inc., Wallingford CT, USA","edition":"E01"},{"key":"9945_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1008763014207","volume":"18","author":"I Massova","year":"2000","unstructured":"Massova I, Kollman PA (2000) Combined molecular mechanical and continuum solvent approach (MM-PBSA\/GBSA) to predict ligand binding. Perspect Drug Discov Des 18:113\u2013135. https:\/\/doi.org\/10.1023\/A:1008763014207","journal-title":"Perspect Drug Discov Des"},{"key":"9945_CR40","doi-asserted-by":"publisher","first-page":"104859","DOI":"10.1016\/j.phrs.2020.104859","volume":"157","author":"DL McKee","year":"2020","unstructured":"McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C (2020) Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 157:104859. https:\/\/doi.org\/10.1016\/j.phrs.2020.104859","journal-title":"Pharmacol Res"},{"key":"9945_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/AABC.S105289","volume":"9","author":"J de Ruyck","year":"2016","unstructured":"de Ruyck J, Brysbaert G, Blossey R, Lensink MF (2016) Molecular docking as a popular tool in drug design, an in silico travel. Adv Appl Bioinform Chem 9:1\u201311. https:\/\/doi.org\/10.2147\/AABC.S105289","journal-title":"Adv Appl Bioinform Chem"},{"key":"9945_CR42","doi-asserted-by":"publisher","first-page":"12493","DOI":"10.1038\/s41598-020-69337-9","volume":"10","author":"R Yoshino","year":"2020","unstructured":"Yoshino R, Yasuo N, Sekijima M (2020) Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates. Sci Rep 10:12493. https:\/\/doi.org\/10.1038\/s41598-020-69337-9","journal-title":"Sci Rep"},{"key":"9945_CR43","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.0c00521","author":"MM Ghahremanpour","year":"2020","unstructured":"Ghahremanpour MM et al (2020) Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med Chem Lett. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00521","journal-title":"ACS Med Chem Lett"},{"key":"9945_CR44","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1021\/acs.biochem.0c00160","volume":"59","author":"B Nutho","year":"2020","unstructured":"Nutho B et al (2020) Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? atomistic insights into the inhibitory. Mech Biochem 59:1769\u20131779. https:\/\/doi.org\/10.1021\/acs.biochem.0c00160","journal-title":"Mech Biochem"}],"container-title":["The Protein Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10930-020-09945-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10930-020-09945-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10930-020-09945-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:29:57Z","timestamp":1667521797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10930-020-09945-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9945"],"URL":"https:\/\/doi.org\/10.1007\/s10930-020-09945-6","relation":{},"ISSN":["1572-3887","1875-8355"],"issn-type":[{"value":"1572-3887","type":"print"},{"value":"1875-8355","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"25 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}